A medical device may comprise a body including a mixture of polyvinylpyrrolidone (“PVP”) and mitomycin. The medical device may be in any size or shape such that the medical device may be inserted into living tissue, including, but not limited to, a lacrimal punctal plug and a stent. The mixture of PVP and mitomycin may be coated on a portion of the medical device, contained within a cavity on the medical device, disposed on the surface of the medical device or configured as part of the medical device such that the mixture of PVP and mitomycin can be delivered to tissue.

A medical device including an internal wetting agent and a copolymer of a silicone monomer and satisfying the following conditions: (1) that the internal wetting agent contains a copolymer of an open-chain compound having an acidic group and an open-chain compound having an amide group; (2) that the internal wetting agent is contained in the range of from 0.1 to 10% by mass with respect to the whole medical device; and (3) that the copolymer of a silicone monomer has a hydroxyl group and that the content ratio of the hydroxyl group in the silicone monomer is in the range of from 0.0005 to 0.01 equivalents/g. A medical device containing an internal wetting agent and having excellent transparency and hydrophilicity can be obtained.

A medical device including an internal wetting agent and a copolymer of a silicone monomer and satisfying the following conditions: (1) that the internal wetting agent contains a copolymer of an open-chain compound having an acidic group and an open-chain compound having an amide group; (2) that the internal wetting agent is contained in the range of from 0.1 to 10% by mass with respect to the whole medical device; and (3) that the copolymer of a silicone monomer has a hydroxyl group and that the content ratio of the hydroxyl group in the silicone monomer is in the range of from 0.0005 to 0.01 equivalents/g. A medical device containing an internal wetting agent and having excellent transparency and hydrophilicity can be obtained.

A method for occluding a blood vessel has steps for encasing a semi-rigid, circular plastic ring, open at one point, in silicon material, forming a bladder along an inside diameter of the silicon material, placing a mixture of sodium and potassium salts and polyacrylamide granules in the bladder, closing and sealing the bladder, forming a pair of opposed stirrups on an outside diameter of the silicon material, spreading the encased plastic ring by the stirrups accomplishing an opening through the ring of an extent enabling the ring to be placed over a blood vessel, placing the encased plastic ring over the blood vessel, releasing the stirrup, allowing the ring and bladder to close around the blood vessel, such that the bladder, constrained by the ring from expanding outward, absorbing moisture by osmosis over time, expands inward, and over a time t fully occludes the blood vessel.

A method for occluding a blood vessel has steps for encasing a semi-rigid, circular plastic ring, open at one point, in silicon material, forming a bladder along an inside diameter of the silicon material, placing a mixture of sodium and potassium salts and polyacrylamide granules in the bladder, closing and sealing the bladder, forming a pair of opposed stirrups on an outside diameter of the silicon material, spreading the encased plastic ring by the stirrups accomplishing an opening through the ring of an extent enabling the ring to be placed over a blood vessel, placing the encased plastic ring over the blood vessel, releasing the stirrup, allowing the ring and bladder to close around the blood vessel, such that the bladder, constrained by the ring from expanding outward, absorbing moisture by osmosis over time, expands inward, and over a time t fully occludes the blood vessel.

Disclosed herein is a biomaterial and a method of use thereof for treating a condition. A biomaterial of the disclosure can be, for example, a surgical article. Implantation of a biomaterial disclosed herein into a subject can treat, for example, cancer.

A tubular nonwoven structure as an active agent carrier (“sleeve”) for the atraumatic treatment of hollow organs, in particular applicable via a balloon catheter, as well as a method for the production thereof, wherein the sleeve is folded about a longitudinal sleeve axis in an initial state and is unfoldable in a final state for attachment to an inner wall of a hollow organ, the tubular sleeve is formed of first biodegradable polymer nanofibers and the folding of the sleeve is directed as pleating about a longitudinal sleeve axis, a medicinal active agent is incorporated into the first polymer nanofibers and/or is arranged in interspaces between the polymer nanofibers, and the first polymer fibers are formed such that the polymer fibers degrade over a period of 2 weeks to 3 months so that the active agent can be delivered to a hollow organ wall in this period of time.

A tubular nonwoven structure as an active agent carrier (“sleeve”) for the atraumatic treatment of hollow organs, in particular applicable via a balloon catheter, as well as a method for the production thereof, wherein the sleeve is folded about a longitudinal sleeve axis in an initial state and is unfoldable in a final state for attachment to an inner wall of a hollow organ, the tubular sleeve is formed of first biodegradable polymer nanofibers and the folding of the sleeve is directed as pleating about a longitudinal sleeve axis, a medicinal active agent is incorporated into the first polymer nanofibers and/or is arranged in interspaces between the polymer nanofibers, and the first polymer fibers are formed such that the polymer fibers degrade over a period of 2 weeks to 3 months so that the active agent can be delivered to a hollow organ wall in this period of time.

A coating for a medical device or appliance may include a fluoropolymer and a polyimide. Such coatings may provide a lubricious exterior surface that facilitates insertion or displacement of a medical device in a body lumen. Some coatings that include a fluoropolymer and a polyimide may, among other functions and characteristics, provide increased strength and/or durability relative to some other coatings.

Compliance control stitch patterns sewn or embroidered into biotextile or medical textile substrates impart reinforcing strength, and stretch resistance and control into such substrates. Compliance control stitch patterns may be customizable to particular patients, substrate implantation sites, particular degenerative or diseased conditions, or desired time frames. Substrates having compliance control stitch patterns sewn or embroidered into them may be used in tissue repair or tissue reconstruction applications.